Savolitinib - Misplaced Pages

(Redirected from Volitinib) Chemical compound Pharmaceutical compound

Savolitinib
Clinical data

Other names	Volitinib
ATC code	None
Identifiers
IUPAC name 3-pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolopyrazine
CAS Number	1313725-88-0
ChemSpider	34501055
UNII	2A2DA6857R
KEGG	D11139
ChEBI	CHEBI:231369
CompTox Dashboard (EPA)	DTXSID801111016
ECHA InfoCard	100.238.920
Chemical and physical data
Formula	C₁₇H₁₅N₉
Molar mass	345.370 g·mol
3D model (JSmol)	Interactive image
SMILES C(c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21
InChI InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1 Key:XYDNMOZJKOGZLS-NSHDSACASA-N

Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. It has been given conditional approval for these indication in China.

References

"Savolitinib" (PDF). Statement on a Nonproprietary Name Adopted by the USAN Council. American Medical Association. 26 October 2016.
"Savolitinib - AstraZeneca/Hutchison China MediTech Limited". AdisInsight. Springer Nature Switzerland AG.
Markham A (September 2021). "Savolitinib: First Approval". Drugs. 81 (14): 1665–1670. doi:10.1007/s40265-021-01584-0. PMID 34455538. S2CID 237344020.

Targeted cancer therapy / antineoplastic agents (L01)

CI monoclonal antibodies ("-mab")

Receptor tyrosine kinase	ErbB: HER1/EGFR (Cetuximab Panitumumab) HER2/neu (Pertuzumab Trastuzumab (+hyaluronidase) Trastuzumab emtansine Trastuzumab deruxtecan Zanidatamab )
Others for solid tumors	EpCAM (Catumaxomab Edrecolomab) VEGF-A (Bevacizumab)
Leukemia/lymphoma	lymphoid: CD3 (Glofitamab, Elranatamab, Mosunetuzumab), CD20 (Glofitamab Ibritumomab Mosunetuzumab Obinutuzumab Ofatumumab Rituximab Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab) myeloid: CD33 (Gemtuzumab ozogamicin)
Other	Amivantamab Atezolizumab (+hyaluronidase) Avelumab Axatilimab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab Cosibelimab Daratumumab Dinutuximab beta Dostarlimab Durvalumab Elotuzumab Enfortumab vedotin Epcoritamab Inotuzumab ozogamicin Ipilimumab Isatuximab Loncastuximab tesirine Mirvetuximab soravtansine Mogamulizumab Moxetumomab pasudotox Naxitamab Necitumumab Nivolumab (+hyaluronidase, +relatlimab) Olaratumab Oportuzumab monatox Pembrolizumab Polatuzumab vedotin Prolgolimab Ramucirumab Retifanlimab Sabatolimab Sacituzumab govitecan Serplulimab Sugemalimab Tafasitamab Talquetamab Tarlatamab Teclistamab Tislelizumab Tisotumab vedotin Toripalimab Tremelimumab Zenocutuzumab Zolbetuximab

Tyrosine kinase inhibitors ("-nib")

Receptor tyrosine kinase

HER1/EGFR and HER2/neu

BRAF

RTK class III: C-kit and PDGFR (Avapritinib
Axitinib
Masitinib
Pazopanib
Ripretinib
Sorafenib
Sunitinib
Toceranib)
FLT3 (Lestaurtinib, Gilteritinib (AXL, ALK, LTK))

VEGFR
- Axitinib
- Cediranib
- Fruquintinib
- Lenvatinib
- Nintedanib
- Pazopanib
- Regorafenib
- Semaxanib
- Sorafenib
- Sunitinib
- Tivozanib
- Toceranib
- Vandetanib

ALK

RET inhibitors: Entrectinib (ALK, ROS1, NTRK), Futibatinib (FGFR2), Infigratinib, Larotrectinib (NTRK), Pemigatinib (FGFR), Pralsetinib, Repotrectinib (ROS1, TRK, ALK), Selpercatinib (VEGFR, FGFR), Vandetanib (VEGFR, EGFR).

c-MET inhibitors: Cabozantinib (VEGFR), Capmatinib, Crizotinib (ALK)

Non-receptor

bcr-abl
- Asciminib
- Bosutinib
- Dasatinib
- Imatinib
- Nilotinib
- Ponatinib
- Radotinib

Src (Bosutinib
Dasatinib)

Janus kinase (JAK)

MAP2K (MEK)

EML4-ALK

Bruton's (BTK)

Other

fusion protein against VEGF (Aflibercept)

proapoptotic peptide against ANXA2 and prohibitin (Adipotide)

exotoxin against IL-2 (Denileukin diftitox)

mTOR inhibitors

hedgehog inhibitors

CDK inhibitors

KRAS inhibitors
- Adagrasib
- Sotorasib

Pi3K inhibitors

Menin inhibitors
- Revumenib

Fibroblast growth factor receptor (FGFR) inhibitors
Erdafitinib
Futibatinib
Infigratinib
Pemigatinib

v t e AstraZeneca
Products	Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide Budesonide/formoterol Budesonide/glycopyrronium bromide/formoterol Candesartan Dapagliflozin Disufenton sodium Durvalumab Eculizumab Esomeprazole Exenatide FluMist Fulvestrant Gefitinib Glycopyrronium bromide/formoterol Goserelin Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast Rosuvastatin Roxadustat Salbutamol/budesonide Savolitinib Saxagliptin Sebelipase alfa Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab Trastuzumab deruxtecan Vandetanib Vaxzevria Ximelagatran Zafirlukast Zolmitriptan
Predecessors and acquired companies	Astra AB Alexion Pharmaceuticals Cambridge Antibody Technology MedImmune Zeneca
People	Tom McKillop Louis Schweitzer
Category Commons

Portal:

Medicine

Categories: